BioDelivery Sciences International, Inc., a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products principally in the areas of pain management and addiction. The company provides its products based on its patented BioErodible MucoAdhesive drug delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug delivery technologies. It offers BELBUCA, a buprenorphine buccal film for the treatment of chronic pain; BUNAVAIL, a buprenorphine and naloxone buccal film for the treatment of opioid dependence; and ONSOLIS, a fentanyl buccal soluble film to treat breakthrough pain in opioid patients with cancer. The company also develops buprenorphine extended release injection, an injectable microparticle formulation of buprenorphine for the treatment of opioid dependence and chronic pain. BioDelivery Sciences International, Inc. has a licensing and development agreement with Evonik Corporation and Meda AB. The company was founded in 1997 and is headquartered in Raleigh, North Carolina.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
SymbolNASDAQ:BDSI
CUSIP09060J10
Phone919-582-9050
Debt
Debt-to-Equity Ratio1.21
Current Ratio3.16
Quick Ratio2.90
Price-To-Earnings
Trailing P/E Ratio-6.79
Forward P/E Ratio-3.88
P/E GrowthN/A
Sales & Book Value
Annual Sales$61.99 million
Price / Sales2.50
Cash FlowN/A
Price / CashN/A
Book Value$0.16 per share
Price / Book16.25
Profitability
EPS (Most Recent Fiscal Year)($0.39)
Net Income$5.28 million
Net Margins-103.01%
Return on Equity-278.79%
Return on Assets-52.34%
Miscellaneous
Employees116
Outstanding Shares59,560,000
Market Cap$171.23 million
BioDelivery Sciences International (NASDAQ:BDSI) Frequently Asked Questions
What is BioDelivery Sciences International's stock symbol?
BioDelivery Sciences International trades on the NASDAQ under the ticker symbol "BDSI."
How were BioDelivery Sciences International's earnings last quarter?
BioDelivery Sciences International, Inc. (NASDAQ:BDSI) announced its quarterly earnings data on Thursday, August, 9th. The specialty pharmaceutical company reported ($0.16) EPS for the quarter, topping the Zacks' consensus estimate of ($0.18) by $0.02. The specialty pharmaceutical company earned $12.18 million during the quarter, compared to analyst estimates of $12.44 million. BioDelivery Sciences International had a negative return on equity of 278.79% and a negative net margin of 103.01%. View BioDelivery Sciences International's Earnings History.
When is BioDelivery Sciences International's next earnings date?
What price target have analysts set for BDSI?
5 equities research analysts have issued twelve-month price targets for BioDelivery Sciences International's shares. Their forecasts range from $4.00 to $5.00. On average, they anticipate BioDelivery Sciences International's stock price to reach $4.30 in the next twelve months. This suggests a possible upside of 65.4% from the stock's current price. View Analyst Price Targets for BioDelivery Sciences International.
What is the consensus analysts' recommendation for BioDelivery Sciences International?
What are Wall Street analysts saying about BioDelivery Sciences International stock?
Here are some recent quotes from research analysts about BioDelivery Sciences International stock:
- 1. Cantor Fitzgerald analysts commented, ". Post 2Q18, we are reiterating our Overweight rating and our 12-month price target of $4.50. BDSI continues to evolve into a commercial- stage company with solid growth from its lead product, Belbuca. During the quarter, Belbuca TRxs were up 80% over 2Q17, and were up 31% over 1Q18. Fundamentally, BDSI continues to perform very well, and with the financing overhang removed, a new CEO and CMO, and with strong additions to the Board, we believe that investors will be rewarded by BDSI’s solid execution in 2018 and beyond." (8/9/2018)
- 2. According to Zacks Investment Research, "BioDelivery secured improved positioning in six new managed care contracts providing preferred access to its key drug, Bunavail. This is expected to boost the drug’s sales and profitability. Meanwhile, launch of its second marketed drug, Belbuca in Canada for severe pain should support sales growth. Appointment of Herm Cukier who has a good track record of bringing growth as its new CEO is expected to bode well for its products. BioDelivery’s shares have outperformed the industry in the past three months. However, given the lackluster performance of Bunavail, BioDelivery decided to reduce spending on the drug. Moreover, the company’s portfolio as well as its pipeline candidates may also face severe competition as it targets a highly genericized and crowded market. Earnings estimates have remained stable ahead of the company’s Q2 earnings release. The company has a mixed record of earnings surprises in recent quarters." (7/24/2018)
- 3. HC Wainwright analysts commented, "Valuation and risks. We assume Belbuca continues to grow rapidly to $125M by 2022 (approximately $150M peak), with BDSI cash- flow positive in 2020, and fully profitable by 2021. Our $3.50 12- month price target is based on a DCF with an 11% WACC discount, and negative -15% terminal growth beyond 2027." (7/6/2018)
Who are some of BioDelivery Sciences International's key competitors?
Some companies that are related to BioDelivery Sciences International include ANI Pharmaceuticals Inc Common Stock (ANIP), Vectura Group (VEGPF), Abeona Therapeutics (ABEO), Urogen Pharma (URGN), Viking Therapeutics (VKTX), Adamas Pharmaceuticals (ADMS), GlycoMimetics (GLYC), AC Immune (ACIU), Progenics Pharmaceuticals (PGNX), Dova Pharmaceuticals (DOVA), Eidos Therapeutics (EIDX), Verastem (VSTM), Collegium Pharmaceutical (COLL), Prothena (PRTA) and ArQule (ARQL).
Who are BioDelivery Sciences International's key executives?
BioDelivery Sciences International's management team includes the folowing people:
- Mr. Ernest Robert De Paolantonio CPA, MBA, CFO, Corp. Sec. & Treasurer (Age 65)
- Mr. Herm Cukier, CEO & Director (Age 52)
- Mr. Scott M. Plesha, Pres (Age 54)
- Mr. Joseph M. Lockhart, Sr. VP of Operations
- Mr. James D. Darnley Jr., VP, Gen. Counsel & Commercial Compliance Officer
Has BioDelivery Sciences International been receiving favorable news coverage?
Media coverage about BDSI stock has been trending somewhat positive recently, Accern reports. Accern rates the sentiment of media coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. BioDelivery Sciences International earned a media and rumor sentiment score of 0.04 on Accern's scale. They also assigned media stories about the specialty pharmaceutical company an impact score of 44.35 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company's share price in the next several days. View Recent Headlines for BioDelivery Sciences International.
Who are BioDelivery Sciences International's major shareholders?
BioDelivery Sciences International's stock is owned by a number of of institutional and retail investors. Top institutional investors include BROADFIN CAPITAL, LLC (7.30%), Royce & Associates LP (3.71%), Cortina Asset Management LLC (3.21%), Stonepine Capital Management LLC (2.49%), BlackRock Inc. (2.01%) and Point72 Asset Management L.P. (1.01%). Company insiders that own BioDelivery Sciences International stock include Barry I Feinberg, Francis E Odonnell Jr, Mark A Sirgo, Niraj Vasisht, Paolantonio Ernest Robert De and Samuel P Sears, Jr. View Institutional Ownership Trends for BioDelivery Sciences International.
Which major investors are selling BioDelivery Sciences International stock?
BDSI stock was sold by a variety of institutional investors in the last quarter, including Stonepine Capital Management LLC, Grandeur Peak Global Advisors LLC, Hikari Power Ltd and GSA Capital Partners LLP. Company insiders that have sold BioDelivery Sciences International company stock in the last year include Francis E Odonnell Jr, Mark A Sirgo and Paolantonio Ernest Robert De. View Insider Buying and Selling for BioDelivery Sciences International.
Which major investors are buying BioDelivery Sciences International stock?
BDSI stock was bought by a variety of institutional investors in the last quarter, including Cortina Asset Management LLC, Point72 Asset Management L.P., Royce & Associates LP, Renaissance Technologies LLC, PNC Financial Services Group Inc., Bank of Montreal Can and BlackRock Inc.. View Insider Buying and Selling for BioDelivery Sciences International.
How do I buy shares of BioDelivery Sciences International?
Shares of BDSI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is BioDelivery Sciences International's stock price today?
One share of BDSI stock can currently be purchased for approximately $2.60.
How big of a company is BioDelivery Sciences International?
BioDelivery Sciences International has a market capitalization of $171.23 million and generates $61.99 million in revenue each year. The specialty pharmaceutical company earns $5.28 million in net income (profit) each year or ($0.39) on an earnings per share basis. BioDelivery Sciences International employs 116 workers across the globe.
How can I contact BioDelivery Sciences International?
BioDelivery Sciences International's mailing address is 4131 PARKLAKE AVENUE SUITE 225, RALEIGH NC, 27612. The specialty pharmaceutical company can be reached via phone at 919-582-9050 or via email at [email protected]
MarketBeat Community Rating for BioDelivery Sciences International (NASDAQ BDSI)
MarketBeat's community ratings are surveys of what our community members think about BioDelivery Sciences International and other stocks. Vote "Outperform" if you believe BDSI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BDSI will underperform the S&P 500 over the long term. You may vote once every thirty days.
